Bellevue Group’s Myriad Genetics MYGN Stock Holding History

Bellevue Group’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-31,900	Closed	-$927K	–	145
2018 Q4	$927K	Buy	+31,900	New	+$1.15M	0.06%	118
2018 Q2	–	Sell	-11,800	Closed	-$349K	–	143
2018 Q1	$349K	Sell	11,800 -200	-2%	-$6.77K	0.03%	123
2017 Q4	$412K	Sell	12,000 -1,000	-8%	-$33.7K	0.04%	128
2017 Q3	$470K	Hold	13,000	–	–	0.05%	125
2017 Q2	$336K	Hold	13,000	–	–	0.04%	131
2017 Q1	$250K	Sell	13,000 -1,000	-7%	-$17.7K	0.03%	130
2016 Q4	$233K	Hold	14,000	–	–	0.05%	120
2016 Q3	$288K	Hold	14,000	–	–	0.05%	119
2016 Q2	$428K	Hold	14,000	–	–	0.08%	113
2016 Q1	$524K	Buy	+14,000	New	+$528K	0.1%	110

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bellevue Group's MYGN Position: Q1 2019 in Review

Bellevue Group sold out of Myriad Genetics (MYGN) in Q1 2019, closing a stake of 31,900 shares — an estimated $927K sold.

Bellevue Group first reported a position in MYGN in Q1 2016 and held it in 10 quarters. The position peaked at $927K in Q4 2018. 262 funds tracked by Wall St. Rank hold MYGN as of Q1 2019.

Bellevue Group reported no remaining Myriad Genetics position as of Q1 2019 after selling out during the quarter.
Bellevue Group sold 31,900 Myriad Genetics shares in Q1 2019, an estimated $927K.
Bellevue Group first reported a position in Myriad Genetics in Q1 2016 and held it in 10 quarters.
Bellevue Group's Myriad Genetics position peaked at $927K in Q4 2018.
262 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2019.

Based on Bellevue Group's 13F filing for Q1 2019, filed 15 May 2019.